Cubist hits new high on top-line Phase III antibiotic data
This article was originally published in Scrip
Cubist Pharmaceuticals's stock reached a new high on 25 November after the company announced top-line results from a Phase III study for its intravenous antibiotic ceftolozane/tazobactam (CXA-201) in the treatment of complicated urinary tract infections (cUTI), including statistical superiority over levofloxacin.
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.